LifeStance Health Group (NASDAQ:LFST) Initiates Share Repurchase Program

LifeStance Health Group (NASDAQ:LFST) announced that its board has initiated a stock buyback program on Wednesday, February 25th, RTT News reports. The company plans to buyback $100.00 million in shares. This buyback authorization permits the company to repurchase up to 3.6% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s management believes its shares are undervalued.

LifeStance Health Group Stock Performance

Shares of LFST traded up $0.27 during mid-day trading on Wednesday, reaching $7.41. 6,148,802 shares of the company’s stock were exchanged, compared to its average volume of 1,661,335. The business’s fifty day simple moving average is $7.12 and its 200-day simple moving average is $6.18. The stock has a market capitalization of $2.88 billion, a PE ratio of -247.00 and a beta of 1.12. LifeStance Health Group has a 52-week low of $3.74 and a 52-week high of $8.30. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.58 and a quick ratio of 1.58.

Analyst Ratings Changes

LFST has been the topic of a number of analyst reports. BTIG Research raised their price target on LifeStance Health Group from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, February 2nd. Zacks Research downgraded LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 5th. BMO Capital Markets began coverage on LifeStance Health Group in a research note on Thursday, November 13th. They set an “outperform” rating and a $8.00 target price for the company. Barclays initiated coverage on LifeStance Health Group in a report on Tuesday, December 9th. They issued an “overweight” rating and a $8.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of LifeStance Health Group in a research note on Monday, December 29th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, LifeStance Health Group presently has an average rating of “Moderate Buy” and an average target price of $9.00.

Trending Headlines about LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Q4 operational and financial beat — Revenue grew 17% to $382.2M, visit volumes +18% and clinician base +9%; Q4 net income of $11.7M and Adjusted EBITDA of $48.8M showed margin improvement and stronger cash flow, supporting the positive reaction. LifeStance Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: 2026 outlook and capital return — Company guided FY2026 revenue $1.615B–$1.655B and Adjusted EBITDA $185M–$205M, and the Board authorized a $100M share repurchase program, both of which support longer‑term valuation. LifeStance Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Analyst/market reaction — Revenue beat consensus and several outlets noted the upside, driving a sharp intraday rally as investors priced improved operating leverage and growth momentum. LifeStance Health Group (NASDAQ:LFST) Posts Better-Than-Expected Sales In Q4 CY2025, Stock Jumps 12.7%
• Neutral Sentiment: Earnings call / transcript — Management hosted the Q4 call and provided details on clinician productivity, margin drivers and guidance assumptions; review the transcript/slides for color on cadence and execution risk. LifeStance (LFST) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Secondary offering by existing holders — Certain selling stockholders filed to offer 25,000,000 existing shares; LifeStance is not selling shares and receives no proceeds. The large proposed resale increases potential supply and could pressure the stock despite operational strength. LifeStance Health Group Announces Launch of Secondary Public Offering
• Negative Sentiment: Mixed EPS reads and volatility risk — Depending on the metric, outlets reported slightly different EPS comparisons (some show a beat on adjusted metrics while others cite a miss vs. a near-term consensus), which can drive short-term volatility; trading volume has been elevated. LifeStance Health Group Inc Earnings Report (MarketBeat)

Insiders Place Their Bets

In other news, Director Robert Bessler sold 119,942 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $7.04, for a total value of $844,391.68. Following the transaction, the director owned 1,318,983 shares of the company’s stock, valued at approximately $9,285,640.32. The trade was a 8.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Ann Varanakis sold 50,000 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $6.90, for a total value of $345,000.00. Following the sale, the insider directly owned 315,610 shares of the company’s stock, valued at approximately $2,177,709. This represents a 13.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 270,086 shares of company stock worth $1,891,264. 3.20% of the stock is currently owned by company insiders.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.